Lucid Diagnostics reports new Medicare, CPT, and ICD-10 panel recommendations supporting reimbursement and coding for its EsoGuard and EsoCheck esophageal cancer tests, advancing billing and clinical tracking pathways.
The FDA has cleared Aptitude’s next-generation Metrix COVID Test, which the company says offers 3-fold higher sensitivity and 30% faster results compared to its EUA version.
A University of Washington study found the panel cross-reacts with 78 gut bacteria species, resulting in over 250,000 false-positive norovirus results since 2019.
VolitionRx reported 95% detection of early-stage solid cancers in blinded validation of its CTCF-protected ctDNA Capture-Seq liquid biopsy, according to data presented at the ESMO MAP Conference.
A nine-lab network evaluated four Bundibugyo virus PCR assays from two manufacturers in two weeks during the 2026 outbreak, establishing new reference standards, according to a study in The Lancet Infectious Diseases.
Researchers at the University of Cambridge report that low levels of placental protein isthmin-2 at 12 weeks gestation may predict risk of pre-eclampsia and fetal growth restriction, according to a study in Nature Medicine.
A Vanderbilt study finds that standard genetic tests for lamotrigine reaction risk omit HLA-A*32:01, a marker linked to severe DRESS, raising concerns about current pharmacogenomic panel effectiveness.
A large trial finds that the rapid 0/1-hour cardiac troponin testing pathway is as safe as standard methods but does not reduce emergency department length of stay or increase direct discharge rates.
Health Canada has approved Fujirebio’s Lumipulse G NfL Blood and pTau 217 Plasma assays, expanding access to blood-based neurology biomarkers for clinical use on the Lumipulse G immunoassay platform.
A University of Exeter study finds that adding a genetic risk score to MODY testing can identify hidden type 1 diabetes in 16% of patients with negative genetic results, supporting updated NHS diagnostic protocols.
A Johns Hopkins study reports that adding three urine biomarkers to standard assessments raises the accuracy of predicting deceased donor kidney transplant success from 80% to 86%.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
A study validates Nu.Q NETs H3.1 nucleosomes as independent predictors of 28-day mortality and renal replacement therapy need in sepsis and septic shock, according to VolitionRx.